Last checked at 29 Apr 2020 17:42
VALIRX PLC
("ValiRx", the "Company" or the "Group")
Statement re social media reports
London, UK., 29 April 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, notes the recent movement in the Company's share price and speculative comments posted on social media in respect of a potential Joint Venture in relation to the Company's non-core intellectual property - GeneICE, TRAC and BioFit.
The Company confirms that it is in talks with a third-party in relation to a Joint Venture. However, there is no certainty the talks will conclude in a successful manner, nor that in the event that the Joint Venture is agreed, that the terms will be favourable to the Company.
-ENDS-
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For more information, please contact:
ValiRx plc | Tel: +44 (0)207 0732628 www.valirx.com |
Kevin Alexander - Non-executive Director | |
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Jo Turner / Ludovico Lazzaretti
| Tel: +44 (0) 20 7213 0880 |
Peterhouse Capital Limited (Sole Broker) Duncan Vasey / Lucy Williams / Eran Zucker
| Tel: +44 (0) 20 7469 0930 |